<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="MC_Biotech Gainer Screening Methodology - SL Mar R&D Notes">
    <title>MC_Biotech Gainer Screening Methodology | SL Mar</title>
    <link rel="stylesheet" href="styles.css">
    <style>
        .article-content {
            max-width: 900px;
            margin: 0 auto;
        }
        .article-content h1 {
            font-size: 2.5rem;
            margin-bottom: 1rem;
        }
        .article-content h2 {
            font-size: 1.75rem;
            margin-top: 2rem;
            margin-bottom: 1rem;
            padding-top: 1rem;
            border-top: 1px solid var(--border);
        }
        .article-content h3 {
            font-size: 1.25rem;
            margin-top: 1.5rem;
            margin-bottom: 0.75rem;
        }
        .article-content p {
            margin-bottom: 1rem;
            line-height: 1.8;
        }
        .article-content ul, .article-content ol {
            margin-left: 2rem;
            margin-bottom: 1rem;
        }
        .article-content li {
            margin-bottom: 0.5rem;
        }
        .article-content code {
            background: var(--bg-secondary);
            padding: 0.2rem 0.4rem;
            border-radius: 3px;
            font-size: 0.9em;
        }
        .article-content pre {
            background: var(--bg-secondary);
            padding: 1rem;
            border-radius: 6px;
            overflow-x: auto;
            margin-bottom: 1rem;
        }
        .article-content pre code {
            padding: 0;
            background: none;
        }
        .article-content table {
            width: 100%;
            border-collapse: collapse;
            margin: 1rem 0;
        }
        .article-content table td {
            padding: 0.5rem;
            border: 1px solid var(--border);
        }
        .back-link {
            display: inline-block;
            margin-bottom: 2rem;
            color: var(--accent);
        }
    </style>
</head>
<body>
    <nav>
        <div class="container">
            <a href="index.html" class="logo">SL Mar - Maritime and AI Consultancy</a>
            <ul>
                <li><a href="index.html">Home</a></li>
                <li><a href="publications.html">Publications</a></li>
                <li><a href="development.html">Development</a></li>
                <li><a href="local-ai.html">Local AI</a></li>
                <li><a href="rnd-notes.html" class="active">R&D Notes</a></li>
                <li><a href="contact.html">Contact</a></li>
            </ul>
        </div>
    </nav>

    <section>
        <div class="container article-content">
            <a href="rnd-notes.html" class="back-link">← Back to R&D Notes</a>
            <h1>MC_Biotech Gainer Screening Methodology</h1>
<strong>Analysis Date:</strong> October 9, 2025
<strong>Data Source:</strong> Perplexity AI analysis of Oct 8, 2025 top gainers</p><h2>Executive Summary</h2><p>Analysis of the top 7 biotech gainers from October 8, 2025 reveals that <strong>most moves were speculative without specific catalysts</strong>, making them extremely difficult to predict with traditional fundamental screening. However, common technical patterns emerged that could be screened.</p><h2>Top Gainers Analyzed</h2><table>
<tr><td>Ticker</td><td>Gain</td><td>Market Cap</td><td>Catalyst</td></tr>
<tr><td>XBIO</td><td>+141-161%</td><td>Micro-cap</td><td>Speculative (no news)</td></tr>
<tr><td>NXL</td><td>+98%</td><td>Micro-cap</td><td>Speculative</td></tr>
<tr><td>ATON</td><td>+95%</td><td>Micro-cap</td><td>Speculative</td></tr>
<tr><td>SCWO</td><td>+92%</td><td>Micro-cap</td><td>Speculative</td></tr>
<tr><td>ACXP</td><td>+88%</td><td>Micro-cap</td><td>Speculative (analyst interest)</td></tr>
<tr><td>UPC</td><td>+83-93%</td><td>Micro-cap</td><td>Speculative</td></tr>
<tr><td>ADAP</td><td>+52%</td><td>Micro-cap</td><td>Speculative</td></tr>
</table><h2>Key Finding: Speculative Trading, Not News-Driven</h2><p><strong>CRITICAL INSIGHT:</strong> These massive gains occurred WITHOUT specific catalysts:
<li>❌ No FDA approvals announced</li>
<li>❌ No clinical trial data releases</li>
<li>❌ No partnership announcements</li>
<li>❌ No regulatory breakthroughs</li>
<li>✅ Speculative trading and sector momentum ONLY</li></ul><h2>Common Pre-Breakout Characteristics</h2><h3>1. Market Cap Profile</h3>
<li><strong>All were micro-caps</strong> (under $300M market cap)</li>
<li>Higher volatility and susceptibility to speculative rallies</li>
<li>Lower liquidity = easier to move on small volume</li></ul><h3>2. Volume Patterns (Predictive Factor)</h3>
<li><strong>5-day volume breakouts</strong> observed before the move</li>
<li>NXL showed 74.70% volume increase in days prior</li>
<li>TNMG showed 67.32% volume increase in days prior</li>
<li><strong>SCREENING CRITERIA:</strong> Volume > 3x average (5-day vs 50-day)</li></ul><h3>3. Technical Indicators</h3>
<li><strong>RSI entering overbought territory (>70)</strong></li>
  - XBIO: RSI 89 (overbought but momentum strong)
  - NXL: RSI 84 (overbought)
  - ATON: RSI 74 (near overbought)
<li><strong>SCREENING CRITERIA:</strong> RSI 60-75 (momentum building, not yet exhausted)</li></ul><h3>4. Price Action Signals</h3>
<li><strong>Bullish chart patterns</strong> (W-bottoms, ascending triangles)</li>
<li><strong>Trend reversals</strong> from recent lows</li>
<li><strong>Breaking above moving averages</strong> (20/50-day)</li>
<li><strong>SCREENING CRITERIA:</strong> Price > 20-day MA AND 50-day MA</li></ul><h3>5. Sector Patterns</h3>
<li><strong>100% biotech/pharma sector concentration</strong></li>
<li>Broad sector rotation into speculative biotech</li>
<li>All stocks moved on <strong>sector momentum</strong>, not individual news</li>
<li><strong>SCREENING CRITERIA:</strong> Sector = Biotech/Pharma</li></ul><h3>6. Pre-Market Activity (Day-Of Signal)</h3>
<li>Significant pre-market trading activity on Oct 8</li>
<li>Early movers: XBIO, UPC, XTLB, ACXP showed gains before market open</li>
<li><strong>SCREENING CRITERIA:</strong> Pre-market volume > 50% of avg daily volume</li></ul><h2>Proposed Screening Methodology</h2><h3>Phase 1: Universe Selection</h3>
<pre><code>
<li>Sector: Biotech / Pharmaceuticals</li>
<li>Market Cap: $50M - $500M (micro-cap focus)</li>
<li>Average Daily Volume: > 100K shares (minimum liquidity)</li>
<li>Exchange: NASDAQ/NYSE (no OTC)</li>
</code></pre><h3>Phase 2: Volume Breakout Detection</h3>
<pre><code>
<li>Current Volume > 3x average volume (5-day vs 50-day)</li>
<li>OR: Volume spike in last 1-3 days (>200% vs avg)</li>
<li>Filter: Sustained volume (not single-day anomaly)</li>
</code></pre><h3>Phase 3: Technical Confirmation</h3>
<pre><code>
<li>RSI(14): Between 60-75 (momentum building, not overbought)</li>
<li>Price Position: Above 20-day MA AND 50-day MA</li>
<li>Chart Pattern: Look for bullish patterns (manual or ML-based)</li>
</code></pre><h3>Phase 4: Pre-Market Monitoring (Day-Of)</h3>
<pre><code>
<li>Pre-market volume > 50% of average daily volume</li>
<li>Pre-market price change > +5%</li>
<li>Early institutional/retail interest signal</li>
</code></pre><h3>Phase 5: Risk Filters</h3>
<pre><code>
<li>Exclude: Recent reverse splits (dilution risk)</li>
<li>Exclude: Bankruptcy filings or delisting warnings</li>
<li>Exclude: SEC investigations or fraud allegations</li>
</code></pre><h2>Implementation Strategy</h2><h3>Option A: Daily Pre-Market Screener (Reactive)</h3>
<strong>Runs:</strong> 8:00 AM ET daily
<strong>Goal:</strong> Catch momentum before market open
<strong>Criteria:</strong>
<li>Biotech micro-caps with pre-market volume spike</li>
<li>Price gapping up >5% pre-market</li>
<li>RSI 60-75 range (from prior day close)</li>
<li>Entry: Market open OR first pullback</li></ul><p><strong>Risk:</strong> Late entry, potential for immediate reversal</p><h3>Option B: Evening Screener (Proactive)</h3>
<strong>Runs:</strong> 5:00 PM ET daily
<strong>Goal:</strong> Identify candidates 12+ hours before potential move
<strong>Criteria:</strong>
<li>Biotech micro-caps with 3x volume breakout (intraday)</li>
<li>Close above 20-day and 50-day MA</li>
<li>RSI 60-75 range</li>
<li>Monitor pre-market the next day for confirmation</li></ul><p><strong>Risk:</strong> Many false positives, requires manual review</p><h3>Option C: Combined Approach (Recommended)</h3>
<li><strong>Evening Screener:</strong> Generate watchlist of 10-20 candidates</li>
<li><strong>Manual Review:</strong> Check for chart patterns, recent news</li>
<li><strong>Pre-Market Filter:</strong> Only trade those showing pre-market momentum</li>
<li><strong>Entry Strategy:</strong> Wait for first 30-min, enter on pullback or breakout confirmation</li></ul><h2>Critical Limitations</h2><h3>1. Speculative Nature</h3>
<li><strong>Most moves had NO fundamental catalyst</strong></li>
<li>Impossible to predict which micro-cap will get speculative interest</li>
<li>High false positive rate (many setups fail)</li></ul><h3>2. Risk Management Essential</h3>
<li><strong>Stop Loss:</strong> 10-15% maximum per position</li>
<li><strong>Position Size:</strong> 0.5-1% of portfolio per trade</li>
<li><strong>Exit Strategy:</strong> Take profits quickly (these moves fade fast)</li></ul><h3>3. Low Repeatability</h3>
<li>Speculative rallies are <strong>not sustainable</strong></li>
<li>Many gainers reverse 50%+ within days</li>
<li>Focus on <strong>momentum capture</strong>, not hold-and-hope</li></ul><h2>Comparison to Current Breakout Flow</h2><h3>Current Tech Sector Breakout Flow</h3>
<li><strong>Sector:</strong> Technology (established companies)</li>
<li><strong>Market Cap:</strong> $300M - $50B (mid/large-cap)</li>
<li><strong>Catalyst:</strong> Volume surge (3x) + technical scoring</li>
<li><strong>Entry:</strong> After 10:00 AM ET (avoids volatility)</li>
<li><strong>Risk:</strong> 1% stop loss, 5% profit target</li></ul><h3>Proposed Biotech Speculative Flow</h3>
<li><strong>Sector:</strong> Biotech/Pharma (micro-caps)</li>
<li><strong>Market Cap:</strong> $50M - $500M (micro-cap)</li>
<li><strong>Catalyst:</strong> Volume breakout + sector momentum (no fundamental news)</li>
<li><strong>Entry:</strong> Pre-market or market open (early momentum)</li>
<li><strong>Risk:</strong> 10-15% stop loss (higher volatility), 20-50% profit target (explosive moves)</li></ul><h3>Key Differences</h3>
<li><strong>Higher Risk/Reward:</strong> Biotech micro-caps = extreme volatility</li>
<li><strong>Earlier Entry:</strong> Must catch momentum at market open (can't wait until 10 AM)</li>
<li><strong>Speculative Nature:</strong> No fundamental validation, pure technical + momentum</li>
<li><strong>Sector Concentration:</strong> 100% biotech = higher portfolio risk if sector rotates</li></ul><h2>Recommended Action</h2><h3>Immediate Next Steps</h3>
<li><strong>Backtest:</strong> Test proposed screening criteria on historical data (Jan-Oct 2025)</li>
<li><strong>Paper Trade:</strong> Run combined approach for 2 weeks without real capital</li>
<li><strong>Validate:</strong> Measure hit rate, avg gain, avg loss, Sharpe ratio</li>
<li><strong>Decide:</strong> Only implement live if backtest shows >60% win rate AND positive expectancy</li></ul><h3>Long-Term Strategy</h3>
<li><strong>Separate Strategy:</strong> Keep biotech speculative flow SEPARATE from tech breakout flow</li>
<li><strong>Portfolio Allocation:</strong> Max 10% of capital to speculative biotech plays</li>
<li><strong>Performance Tracking:</strong> Monitor separately, adjust/kill if underperforming</li></ul><h2>Conclusion</h2><p><strong>The October 8, 2025 biotech gainers were driven by speculative momentum, not news catalysts.</strong> While common technical patterns exist (volume breakouts, RSI momentum, micro-cap profile), predicting WHICH stock will explode is extremely difficult.</p><p><strong>Success requires:</strong>
<li>High volume of candidates (cast wide net)</li>
<li>Strict risk management (small position sizes, tight stops)</li>
<li>Quick profit-taking (momentum fades fast)</li>
<li>Acceptance of low hit rate (~40-60%) offset by large wins</li></ul><p><strong>This is NOT a "set and forget" strategy.</strong> It requires active monitoring, fast execution, and comfort with high volatility.</p><p>---</p><p><strong>Status:</strong> Draft for review
<strong>Next Step:</strong> Backtest proposed methodology on historical data before live implementation
<strong>Author:</strong> Claude Code (MC_ prefix indicates machine-created draft)
</p>
        </div>
    </section>

    <footer>
        <div class="container">
            <p>&copy; 2025 SL Mar</p>
            <p>AI for Quantitative Finance and Maritime Applications</p>
            <p>France • SIRET 98770400400017</p>
        </div>
    </footer>
</body>
</html>